Sangamo Therapeutics, Inc. - Common Stock (SGMO)

U.S. stock futures were flat on Tuesday after a bounce back on Monday. Futures of all four benchmark indices were mixed in premarket trading.

Several optimistic users expressed confidence in the company securing a third potential agreement with a major pharma for its adeno-associated virus (AAV) capsid, STAC-BBB.

Pfizer has discontinued Beqvez for hemophilia B due to low patient demand and will focus on alternative treatments, including its approved therapy, Hympavzi.

Stocks are lower midday, as Wall Street heads for its second consecutive winning year.

Sangamo Therapeutics regains rights to its hemophilia A gene therapy as Pfizer ends their collaboration. The program showed positive Phase 3 results.

U.S. stock futures were trading higher on Tuesday following Monday's selloff. All four index futures rose in trade.

U.S. stock futures down, investors eye EHang, Sangamo, Cemtrex, CompoSecure, Ambow. Check out Benzinga's premarket coverage & top tech stocks to watch.

U.S. stock futures climbed on Thursday in premarket hours after a hawkish cut from the Federal Reserve on Wednesday.